We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+18.18%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$478M
AUM Growth
-$35.8M
Cap. Flow
-$112M
Cap. Flow %
-23.36%
Top 10 Hldgs %
71.33%
Holding
31
New
1
Increased
7
Reduced
12
Closed
1

Top Buys

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$11.1M
2
QLTI
QLT Inc
QLTI
+$6.17M
3
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$2.9M
4
LITS
Lite Strategy Inc
LITS
+$2.69M
5
ARQL
Arqule Inc
ARQL
+$2.31M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45.8M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$36.4M
3
ARRY
Array Biopharma Inc
ARRY
+$16.8M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$8.16M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 62.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$69.3M 14.5%
9,405,817
-2,366,518
-20% -$16.8M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$62.7M 13.11%
8,303,084
-293,688
-3% -$2.29M
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$647M
$34.7M 7.26%
2,592,303
-3,489,706
-57% -$45.8M
FWP
4
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$33.3M 6.97%
168,212
+17,872
+12% +$2.9M
OMED
5
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$33.1M 6.92%
1,284,115
-90,700
-7% -$2.3M
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
$23.3M 4.88%
2,385,696
+91,986
+4% +$902K
LGND icon
7
Ligand Pharmaceuticals
LGND
$5.87B
$20.6M 4.31%
428,145
-950,536
-69% -$36.4M
CNCE
8
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$20.3M 4.25%
1,340,659
+134,200
+11% +$1.87M
GYRE icon
9
Gyre Therapeutics
GYRE
$644M
$19.8M 4.13%
8,451
– –
VTAE
10
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$18.5M 3.86%
1,577,435
+823,500
+109% +$11.1M
QLTI
11
DELISTED
QLT Inc
QLTI
$16.2M 3.39%
4,149,862
+1,499,299
+57% +$6.17M
CYTK icon
12
Cytokinetics
CYTK
$10.8B
$14.3M 2.99%
2,106,989
-336,111
-14% -$2.51M
LOXO
13
DELISTED
Loxo Oncology, Inc
LOXO
$14M 2.93%
1,125,665
-65,037
-5% -$810K
ARQL
14
DELISTED
Arqule Inc
ARQL
$13.8M 2.89%
6,174,561
+1,450,750
+31% +$2.31M
EXEL icon
15
Exelixis
EXEL
$13.8B
$12.8M 2.68%
4,988,357
+793,005
+19% +$1.84M
FPRX
16
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$11.5M 2.4%
502,832
-323,500
-39% -$8.16M
ONCT
17
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$7.51M 1.57%
7,937
– –
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.12B
$6.6M 1.38%
391,424
-226,800
-37% -$4.19M
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.64M 0.97%
9,014
-5,919
-40% -$2.99M
SVRA icon
20
Savara
SVRA
$1.13B
$3.51M 0.73%
103,451
-715
-0.7% -$24.9K
BLRX
21
BioLineRX
BLRX
$11.5M
$3.17M 0.66%
2,502
– –
ACHV icon
22
Achieve Life Sciences
ACHV
$646M
$2.94M 0.62%
622
– –
TBRA
23
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.3M 0.48%
209,169
– –
AKAO
24
DELISTED
Achaogen Inc
AKAO
$1.33M 0.28%
136,600
– –
LITS
25
Lite Strategy Inc
LITS
$30.9M
$1.07M 0.22%
+30,000
New +$2.69M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2015 Portfolio in Review

As of Q1 2015, BVF Inc held 31 positions worth $478M, down 7% from $514M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

BVF Inc withdrew a net $112M in Q1 2015, closing 1 position and reducing 12 holdings. Its most notable exit was Anthera Pharmaceuticals, Inc., an estimated $884K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 71% a quarter earlier.

Against the trend, BVF Inc opened a new position in Lite Strategy Inc worth $1.07M.

  • BVF Inc's largest Q1 2015 buy was Lite Strategy Inc: 30,000 shares worth $1.07M.
  • BVF Inc added most to VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015, an estimated $11.1M increase.
  • BVF Inc's biggest Q1 2015 reduction was Ironwood Pharmaceuticals, cutting an estimated $45.8M.
  • BVF Inc fully exited Anthera Pharmaceuticals, Inc. in Q1 2015, selling an estimated $884K.
  • BVF Inc's ten largest holdings make up 71% of its $478M portfolio in Q1 2015.
  • BVF Inc opened 1 new position and closed 1 in Q1 2015.
  • BVF Inc's portfolio value fell 7% quarter-over-quarter to $478M.

Based on BVF Inc's 13F filing for Q1 2015, filed 15 May 2015.